TREATMENT WITH APELIN AND ANALOGUES IMPROVES WOUND HEALING IN DIABETIC MICE

Abstract

People with diabetes are uniquely susceptible to diabetic foot ulceration (DFU) and lower extremity amputation (LEA). Indeed, patients with diabetes are more vulnerable to injuries creating hard-to-heal or non-healing wounds and increasing the risk of infection and amputation. Although the complex pathophysiology leading to DFU involves the synergistic effect of multiple mechanical, biological and molecular processes, diabetes impairs the angiogenic process while preventing delivery of oxygen, nutrients and immune proper response to fight the infection. Interestingly, our laboratory has shown that stimulation of the apelinergic system with pyr-apelin-13 (pyr-ape-13) or pyr-ELABELA-32 (pyr-ELA-32) improved blood flow reperfusion in diabetic mice following hind limb ischemia. Our objective is to evaluate the potential therapeutic effect of apelinergic system in a diabetic wound healing model.